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ORIGINAL ARTICLE
Narrowband Ultraviolet B Phototherapy of Early Stage 
Mycosis Fungoides in Korean Patients
Min Soo Jang, M.D., Jae Woo Baek, M.D., Jong Bin Park, M.D., Dong Young Kang, M.D., 
Jin Seuk Kang, M.D., Kee Suck Suh, M.D., Sang Tae Kim, M.D.
Department of Dermatology, Kosin University College of Medicine, Busan, Korea
Background: Narrowband UVB (NBUVB) is currently used 
to treat early mycosis fungoides (MF). There are a number of 
reports on the efficacy and safety of NBUVB in Caucasians, 
but little data is available for Asians. Objective: This study 
was designed to evaluate the effectiveness and safety of 
NBUVB for early stage MF in Korean patients. Methods: We 
enrolled 14 patients (12 men, 2 women; age range, 10∼64 
years) with clinically and histologically proven MF. Three 
patients were stage IA, and the others were stage IB. The 
patients received NBUVB phototherapy three times a week. 
The starting dose was 70% of the minimal erythema dose and 
was increased in 20 percent increments if the previous 
treatment did not cause erythema. Clinical response, total 
number of treatments, total cumulative dose, duration of 
remission and side effects were investigated. Results: Eleven 
of 14 patients (78.6%) achieved complete remission within 
a mean of 15.36±5.71 weeks (range, 5∼27 weeks), 
31.0±7.4 treatments (range, 16∼39 treatments) and a mean 
cumulative UVB dose of 31.31±12.16 J/cm
2 (range, 11.4∼
46.8 J/cm
2). Three of the 14 patients (21.4%) achieved a 
partial remission. After discontinuation of treatment, 6 of 11 
patients (54.5%) with complete remission relapsed after a 
mean of 8.5±4.09 months. No serious adverse effects were 
observed except for hyperpigmentation (7/14, 50%). 
Conclusion: Our data suggest that NBUVB therapy is safe 
and effective for the treatment of early stage MF in Korean 
patients. (Ann Dermatol 23(4) 474∼480, 2011)
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INTRODUCTION
Mycosis fungoides (MF) is the most common form of 
cutaneous T-cell lymphoma. MF, which has been termed 
the “great imitator”, presents with a variety of clinical 
features and nonspecific histological findings, especially 
in early lesions
1-3. According to its natural course and 
prognosis, MF is classified into early (stage IA, IB and IIA) 
and advanced (stage IIB, III and IV) stages. Early MF 
presents as a variety of patches and plaques without 
internal involvement, and may progress to a more 
advanced stage. Currently, the treatment of early-stage MF 
includes topical agents (corticosteroid, nitrogen mustards, 
carmustine and bexarotene), electron beam therapy and 
phototherapy (oral psoralen plus UVA, broadband UVB, 
narrowband UVB, UVA-1, excimer laser, photodynamic 
therapy). Among these therapeutic options, narrowband 
UVB (NBUVB) is safe and convenient in comparison to 
the other treatments. To date, a number of reports have 
shown that NBUVB phototherapy is effective for early 
stage MF. However, these studies typically involve patients 
in Western populations, and there are a lack of studies on 
the therapeutic effects of NBUVB on early MF in Asian 
patients, who have a different skin phototype. In this 
study, we analyzed the efficacy and safety of NBUVB in 
Korean patients with early-stage MF.Narrowband Ultraviolet B Phototherapy of Early Stage Mycosis Fungoides in Korean Patients
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Table 1. Clinical characteristic of study patients with early stage mycosis fungoides 
Case Age/Sex Phototype Duration 
(month) Site Symptom Clinical findings Stage
(TNM)
 1 47/M IV 4 Whole body Pruritic Patch IB
 2 32/M IV 24 Trunk, both extremities Asymptomatic Patch, hypopigmented IB
 3 22/F V 24 Thigh, leg (right) Asymptomatic Patch IB
 4 10/M IV 2 Whole body Asymptomatic Papule, PL-like* IB
 5 15/M III 132 Whole body Pruritic Papule IB
 6 50/M IV 1 Trunk  Asymptomatic Patch IB
 7 60/M V 120 Trunk, both extremities Asymptomatic Patch IB
 8 16/M IV 156 Trunk, both extremities Asymptomatic Patch, hypopigmented IB
 9 33/M IV 120 Whole body Asymptomatic Patch IB
10 19/M IV 14 Whole body Pruritic Papule, PL-like* IB
11 21/M III 6 Neck Pruritic Patch, ichthyosiform IA
12 30/M IV 36 Whole body Pruritic Patch IB
13 36/M III 12 Both lower legs Pruritic Patch IA
14 64/F IV 10 Submammary Asymptomatic Patch IA
M: male, F: female, *PL-like: pityriasis lichenoides.
MATERIALS AND METHODS
Patients
Fourteen patients, who were clinically and histologically 
diagnosed with MF between June 2007 and April 2010, 
were enrolled in this study after providing informed 
consent for treatment. According to the TNM staging
4 
proposed in 2007 by the International Society of Cuta-
neous Lymphoma/European Organization of Research and 
Treatment of Cancer, all patients were classified as stage 
IA or IB. All patients were treated with NBUVB photo-
therapy alone without being combined with topical 
steroid or topical chemotherapy during the course of the 
study. 
We excluded any patient who had a history of photo-
sensitivity disease or who was being treated with photo-
sensitizing medication. Six patients had received a pre-
vious treatment other than NBUVB, such as topical steroid 
or psoralen UVA (PUVA), but they did not receive any 
treatment at least 6 months prior to starting NBUVB.
Irradiation course and protocol
The NBUVB irradiation was performed in a UV7001K 
phototherapy cabinet (Waldmann, Villingen-Schwen-
ningen, Germany) equipped with TL-01 lamps (Philips 
Lighting BV, Roosendaal, Netherlands) emitting NBUVB 
wavelengths between 311 and 313 nm. Each patient’s 
minimal erythema dose (MED) was determined before the 
start of irradiation. The initial treatment dose was 70% of a 
patient’s individual MED, with subsequent incremental 
increases of 20% if the previous treatment caused no or 
slight erythema. Most patients received irradiation 3 times 
weekly, continuing treatment until there was more than 
95% clearing of the patient’s skin lesions. 
Evaluation of therapeutic efficacy
Responses to phototherapy were clinically assessed by 
two independent dermatologists using clinical photo-
graphs with the same digital camera (α350, Sony, Tokyo, 
Japan) in the same position under controlled lighting 
conditions at each follow-up visit. Clinical responses to 
treatment were classified as complete response (＞95% 
clearance of lesions), partial response (50∼95% clearance), 
and no response (＜50% clearance). Any adverse effects 
such as erythema, hyperpigmentation, hypopigmentation, 
pruritus, and xerosis were also assessed at each visit. 
RESULTS
Clinical manifestations (Table 1)
Of the 14 patients, 12 were male and 2 were female with 
ages ranging from 10 to 64 years (mean, 32.5±17.1 
years), while the mean duration of skin lesions before 
diagnosis was 47.2±57.0 months. All patients had Fitzpa-
trick skin types ranging from III to V (4 for III, 8 for IV and 
2 for V, respectively). Six patients (42.9%) complained of 
pruritus, but the others (57.1%) were asymptomatic. All of 
the patients presented clinically with patches and papules, 
but none of them had plaques: 12 presented with patches 
and the other 2 with papules. Three of the 14 patients 
were stage IA (21.4%), the other 11 (78.6%) were stage 
IB. MS Jang, et al
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Table 2. Phototherapeutic data of patients with early stage mycosis fungoides treated with NBUVB
Case No. of
treatments
Treatment 
duration
(week)
Cumulative dose 
(J/cm
2 )
Clinical 
response Side effects
Follow-up
period
(month)
Recurrence-free
period
(month)
 1 34 18 40.3 CR Hyperpigmentation 16 −
 2 39 20 46.8 CR Hyperpigmentation 23 −
 33 2 1 3 3 3 P R 3 0
 4 32 10 31.8 CR Hyperpigmentation 26 −
 5 16 5 11.4 CR 25  6
 6 36 13 40.8 CR 15 12
 71 9 1 0 2 9 P R 1 1
 8 30 27 17.8 CR Hyperpigmentation 19 −
 9 37 14 42.1 CR Hyperpigmentation 14 10
10 34 14 17.8 CR Hyperpigmentation  8  5
11 19  8 11.4 CR Xerosis  6 −
12 36  9 20.3 CR Hyperpigmentation 11  4
13 28 16 30.6 CR Erythema 21 14
14 23  7 24 PR  9
NBUVB: narrowband UVB, CR: complete remission, PR: partial remission.
Table 3. The phototherapeutic results of 14 patients with early mycosis fungoides
Total No.
of patients
Mean No. of 
treatments±SD
Mean treatment 
duration±SD 
(week)
Mean cumulative 
dose (J/cm
2) CR (%) PR (%)
Mean follow-up 
period±SD 
(months)
Mean recurrence-free 
period±SD
(months)
14 31.0±7.4 15.36±5.71 31.31±12.16 11/14 (78.6) 3/14 (21.4) 16.45±7.16 8.5±4.09
SD: standard deviation, CR: complete remission, PR: partial remission.
Table 4. The therapeutic outcome by TNM stage
TNM stage Total No. 
of patients
Mean No. of 
treatments±SD
Mean treatment 
duration±SD (week)
Mean cumulative 
dose (J/cm
2)  CR (%) PR (%) Relapse (%)
IA  3 23.33±4.51 10.33±4.93 23.70±7.05 2 (66.7) 1 (33.3) 1 (33.3)
IB 11 31.36±7.34 13.91±6.01  32.67±11.16 9 (81.8) 2 (18.2) 5 (45.5)
SD: standard deviation, CR: complete remission, PR: partial remission.
Therapeutic effects (Tables 2∼4)
Of the 14 treated patients, complete and partial responses 
were observed in 11 (78.6%) and 3 (21.4%) patients, 
respectively (Fig. 1, 2). The mean number of treatments in 
patients with a complete response was 31.0±7.4 within a 
mean time of 15.4±5.71 weeks (range, 5∼27 weeks) and 
the cumulative dose was 31.3±12.2 J/cm
2 (range, 15.3∼
46.8  J/cm
2). Six (54.5%) of the 11 patients with complete 
response recurred after a mean follow-up period of 
8.5±4.1 months (range, 5∼25 months). A complete 
response according to the stage was achieved in 66.7% 
and 81.8% in stage IA and IB, respectively. For stage IA, 
the mean number of treatments was 23.3±4.5, and the 
cumulative dose was 23.7±7.0 J/cm
2, whereas, in stage 
IB, the mean number of treatments was 31.4±7.3, and the 
cumulative dose was 32.7±11.2 J/cm
2.
Side effects
Mild erythema (1 of 14) and hyperpigmentation (7 of 14) 
were noted, but no significant side effects such as blister, 
ulceration or human herpes infection reactivation were 
observed during or after the treatments. 
DISCUSSION
MF, particularly in its early stages, may clinically and 
histologically mimic benign inflammatory dermatoses Narrowband Ultraviolet B Phototherapy of Early Stage Mycosis Fungoides in Korean Patients
Vol. 23, No. 4, 2011 477
Fig. 1. (A) Patch-stage mycosis 
fungoides with erythematous pat-
ches on the trunk. (B) Complete 
clinical remission after 36 treat-
ments of narrowband UVB (case 6).
Fig. 2. (A) Patch-stage mycosis 
fungoides with erythematous pat-
ches on whole dody. (B) Complete
clinical remission with only residual
hyperpigmentation after 37 treat-
ments of narrowband UVB (case 9).
including atopic dermatitis, psoriasis and seborrheic 
dermatitis, thus making it difficult to diagnose. Patients 
with early MF commonly have an indolent and chronic 
course with recurrence, but rarely progress to more 
aggressive course if not treated in time. Therefore, 
appropriate therapeutic decision and treatment are im-
portant in terms of prognostic significance.
Selection of treatment is often determined by various 
factors including age, stage, extent of involvement and 
experience of physician. Since a variety of reviews and 
outcomeshave been reported to try and provide a more 
rational criteria for  the management of MF, skin directed 
therapy (SDT) is currently recognized as the optimal 
treatment for early-stage MF
5-7. SDT includes topical 
corticosteroids, topical chemotherapy (nitrogen mustard, 
carmustine), topical bexarotene, phototherapy and electron 
beam therapy. Of these treatments, topical therapies, 
which have been used for patients with limited patch 
lesions, include potential adverse events (telangiectasia, 
allergic contact dermatitis, skin atrophy and skin cancer, 
etc.) and are unsuitable for controlling extensive lesions. 
Electron beam therapy is also associated with several side 
effects including exfoliation, alopecia, telangiectasia and 
pigmentation. In patients with more widespread lesions, 
or in those for whom topical treatments have been inef-
fective, phototherapy is suitable. Since PUVA was firstly 
reported as phototherapy for MF in 1976 by Gilchrest et 
al.
8, phototherapeutic modalities with various light sources 
have been applied. To date, phototherapeutic options for 
MF published in the literatures include PUVA, NBUVB, 
broadband UVB (BBUVB), UVA-1, photodynamic therapy 
and excimer laser. Of the various phototherapeutic 
options, PUVA and NBUVB have been used as the most 
common phototherapies for patch and plaque MF. In 
addition to NBUVB and PUVA, photodynamic therapy, 
excimer laser, and UVA-1 have been studied in small case 
series
9-11. However, the efficacy and safety of these 
modalities have not been determined, and these treatments 
limited due to their relatively narrow therapeutic extent. 
The advantages of PUVA over NBUVB, including long- MS Jang, et al
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Table 5. Results of narrowband UVB treatment in early-stage mycosis fungoides compared with data in the literature
No. patients
No. of 
treatments
(mean)
Treatment 
period
(months)
Mean cumulative 
dose
(J/cm
2)
CR 
(%)
PR  
(%)
Relapse-free 
survival
(months)
Hofer et al.
16  6 20 1.4 17.2 83 17 6
Clark et al.
17  8 26 2.2 Unknown 75 25 20
Gathers et al.
18 24 52.2 4.4 96.7 54 29 13
Diederen et al.
12 21 112 14 31.8 81 19 24.5
Ghodsi et al.
19 16 27.9 Unknown 26 75 19 4.5
Boztepe et al.
20 14 22.7 2 75.7 78 7 26
Pavlotsky et al.
21 68 Unknown 3.2 29 81 6 Unknown
Gökdemir et al.
22 23 36.2 4.5 90.3 91 9 10.9
Coronel-Pérez et al.
23 23 43 unknown 64.84 57 35 Unknown
Brazzelli et al.
24 20 29 4 25 90 10 8
Ponte et al.
15 19 37 12.3 73.4 68 26 14
Our study 14 31 3.5 31.3 78.6 21.4 8.5
CR: complete remission, PR: partial remission.
term therapeutic response, deeper penetration into the 
skin, and possibility of once-a-month maintenance, have 
been reported in some studies. However, PUVA has side 
effects including nausea, headache, light-headedness, the 
need for sun protection and higher risk for skin cancer. 
There are some studies comparing efficacy and safety of 
NBUVB and PUVA in patients with early stage MF
12-15. 
Most of these comparative studies have shown that both 
NBUVB and PUVA achieve similar results in terms of 
complete remission rates and the mean relapse-free 
interval. 
Recently, NBUVB, which has a lower incidence of 
adverse events and a similar efficacy to other photodynamic 
therapies, has become the treatment-of-choice for early 
stage MF. The first report of NBUVB in early MF was 
published by Hofer et al.
16 in 1999. In this study, complete 
remission in 5 out of 6 patients was achieved after a mean 
of 20 treatments and 17.2 J/cm
2 cumulative doses, and 
relapses were reported in all patients within a mean of 6 
months after discontinuation of treatment. Since then, the 
efficacy of NBUVB for treating early stage MF has been 
reviewed through a variety of protocols
12,15,17-24 (Table 5). 
However, previous clinical reports have, for the most part, 
been conducted in Caucasians, while there has generally 
been little research on Asians. Some authors have also 
found that patients with darker skin types are less 
responsive to NBUVB phototherapy
18. These resistances 
to phototherapy are associated with the photoprotective 
function of melanin, which can absorb radiation from 
various spectrums. However, Kural et al.
25 suggested that 
the stage of MF is more crucial than Fitzpatrick skin 
phototype in determining the response to NBUVB. In our 
study, all patients were assessed for therapeutic response 
according to Fitzpatrick skin phototype and stage, in order 
to investigate the efficacy of NBUVB in higher skin 
phototypes. We found that a higher Fitzpatrick skin 
phototype was significantly less responsive to photo-
therapy. Furthermore, there are no significant difference in 
therapeutic between stage IA and IB. However, it is 
difficult to evaluate accurately the response rate according 
to stage because of small subjects of stage IA and various 
locations of the lesions. Actually, only stage IA patient 
showing partial response after NBUVB phototherapy 
presented patch lesion at submammary area, which may 
be the possibility of insufficient irradiation. Moreover, 
patients with higher stages required more treatments and a 
higher cumulative dose to induce complete remission.
Although the mechanism for NBUVB phototherapy in MF 
has not yet been established, the therapeutic mechanism 
may involve changes in cell cycle kinetics, or alterations 
in cytokine expression and immunomodulation
15. Several 
studies have reported that NBUVB induces an increase in 
expression of IL-2, IL-6 and TNF-α  by human 
keratinocytes and a decrease in the allo-activating and 
antigen-presenting capacity of Langerhans cells
26,27. 
Additionally, NBUVB may suppress the neoplastic 
proliferation of clonal T-cells and serve as an up-regulator 
of the immune system
28. We also suggest that NBUVB 
may directly induce apoptosis of atypical lymphocytes, 
which confined to epidermis and papillary dermis. 
Assessment of the response to phototherapy in MF is based 
on clinical, histopathological and molecular findings. 
Especially, clinical assessment is commonly used and is 
easy to apply, but regular inspection and experience of Narrowband Ultraviolet B Phototherapy of Early Stage Mycosis Fungoides in Korean Patients
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physician is required. Gökdemir et al.
22 found that clinical 
remission correlates with histopathological improvement, 
especially for patch lesions. On the other hand, Dereure 
et al.
29 suggested that clinically defined complete re-
mission does not mean a complete histological response. 
It has also been demonstrated that a deficient histological 
response and the presence of a dominant T cell clone are 
related to a high rate of recurrences.
Whether maintenance treatment is needed for longer 
duration of remission is still debatable.  Some studies have 
indicated that maintenance treatment after complete 
remission may prolong relapse-free intervals or may 
reduce relapse
12,20. On the other hand, some authors have 
advocated that maintenance treatment should be stopped 
completely following the first complete remission, because 
ongoing treatment may increase the risk of skin cancer or 
lead to progression to the higher stage of MF due to 
UVB-induced DNA damage
21,29.
The acute side effects of NBUVB include erythema, edema, 
blistering, pruritus, and reactivation of herpes simplex 
virus, but these usually resolve within several days
30. 
Although previous studies have described a possibility of 
photoaging and carcinogenesis in association with 
NBUVB, there is still no evidence that this occurs. There 
have also been some reports that NBUVB is much safer 
than PUVA
17,18,31. In our study, hyperpigmentation (50%) 
was more common due to the higher skin phototype 
compared to other studies, but no significant side effects, 
aside from mild erythema, were observed. Moreover, we 
found that all patients showing hyperpigmentation after 
NBUVB phototherapy achieved a complete response. We 
also suggest that it might play a role of predictive marker 
of response to NBUVB phototherapy in Asians.
The prognosis for patients with early stage mycosis 
fungoides is favorable. In fact, the survival of patients with 
stage IA or IB MF is not affected by the disease, but 
management of early MF is important in term of life 
quality and prevention of progression.
In our experience, the treatment for early MF should be 
selected according to clinical presentations (patch or 
plaque), regardless of TNM stage of MF. Especially, 
patients with clinically defined lesions of patches and thin 
plaques are highly responsive to NBUVB phototherapy. 
Additionally, we suggest that PUVA is suitable for patients 
who have clinically thick plaques or who are unres-
ponsive to NBUVB. In conclusion, NBUVB phototherapy 
is an effective and safe treatment for early stage MF in 
Asians. However, our study is limited because we did not 
perform a histopathological assessment after treatment. 
Further prospective studies are still necessary to determine 
the therapeutic effects and side effects of NBUVB photo-
therapy in Koreans. 
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